NCT03828084View on ClinicalTrials.gov

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

May 2, 2019

Study Completion Date

May 3, 2019

Conditions
Healthy
Interventions
DRUG

Decitabine

Combination drugs containing decitabine and tetrahydrouridine

Trial Locations (1)

78217

Worldwide Clinical Trial, San Antonio

Sponsors

Lead Sponsor

EpiDestiny, Inc.
All Listed Sponsors
lead

EpiDestiny, Inc.

INDUSTRY

NCT03828084 - Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects | Biotech Hunter | Biotech Hunter